Methodically screening and successfully validating new natural materials as medicines begins with the intersection of these two fields, ethnopharmacology and pharmacognosy. New natural remedies have been developed as a result of traditional knowledge of plants, minerals, and animals. Ethnomedicine is the source of many of the most clinically significant medications used today, including morphine, quinine, and artemisinin. The pharmacological properties, modes of action, and safety profiles of bioactive chemicals are evaluated by controlled, biopharmaceutical, pre-clinical, and in vivo research. There is substantial evidence of bioactives (such as flavonoids, terpenoids, polyphenols, alkaloids, saponins, and resveratrol) modulating corresponding molecular pathways, as well as regulating enzyme activity and receptor interactions, as well as large-scale anti-inflammatory, antioxidant, antimicrobial, antidiabetic, and anticancer activity. Although animal experiments are excellent for reproducibility and mechanistic insights, they are complicated by interspecies heterogeneity, extract variability, bioavailability, and ethical issues that call for additional in vitro, computer model, and clinical trials. Standardised extracts, the creation of bioactive formulations that target multiple modes of action, and the environmentally responsible sourcing of medicinal plants that connect traditional and modern pharmacotherapy should be the main priorities of the future. These studies demonstrate the translational potential of agents derived from ethnopharmacology, validating the wisdom of our ancestors' traditions while also offering the chance to safely explore beneficial phytotherapeutics to meet the health care needs of contemporary society.
Dudhmal et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: